Bull Flag Stocks
PTGX is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
PROTAGONIST THERAPEUTICS INC (PTGX) Stock Price & Overview
NASDAQ:PTGX • US74366E1029
Current stock price
102.09 USD
-1.66 (-1.6%)
At close:
102.09 USD
0 (0%)
After Hours:
The current stock price of PTGX is 102.09 USD. Today PTGX is down by -1.6%. In the past month the price increased by 5.19%. In the past year, price increased by 139.54%.
PTGX Key Statistics
52-Week Range41.285 - 107.84
Current PTGX stock price positioned within its 52-week range.
1-Month Range90.58 - 107.84
Current PTGX stock price positioned within its 1-month range.
- Market Cap
- 6.514B
- P/E
- N/A
- Fwd P/E
- 54.13
- EPS (TTM)
- -2.05
- Dividend Yield
- N/A
PTGX Stock Performance
Today
-1.6%
1 Week
-3.14%
1 Month
+5.19%
3 Months
+27.26%
Longer-term
6 Months +17.34%
1 Year +139.54%
2 Years +306.57%
3 Years +351.73%
5 Years +252.76%
10 Years N/A
PTGX Stock Chart
PTGX Stock Screens
PTGX currently appears in the following ChartMill screener lists.
PTGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 94.66% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PTGX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PTGX. No worries on liquidiy or solvency for PTGX as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PTGX Earnings
On February 25, 2026 PTGX reported an EPS of -0.69 and a revenue of 7.44M. The company missed EPS expectations (-38.48% surprise) and missed revenue expectations (-18.32% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.69
Revenue Reported7.437M
EPS Surprise -38.48%
Revenue Surprise -18.32%
PTGX Forecast & Estimates
19 analysts have analysed PTGX and the average price target is 114.5 USD. This implies a price increase of 12.15% is expected in the next year compared to the current price of 102.09.
For the next year, analysts expect an EPS growth of 192.01% and a revenue growth 764.28% for PTGX
Analysts
Analysts84.21
Price Target114.5 (12.16%)
EPS Next Y192.01%
Revenue Next Year764.28%
PTGX Groups
Sector & Classification
PTGX Financial Highlights
Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS decreased by -148.81% compared to the year before.
Income Statements
Revenue(TTM)46.02M
Net Income(TTM)-130.15M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.48% | ||
| ROE | -21.17% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-134.85%
Sales Q2Q%-95.64%
EPS 1Y (TTM)-148.81%
Revenue 1Y (TTM)-89.41%
PTGX Ownership
Ownership
Inst Owners111.7%
Shares63.81M
Float61.59M
Ins Owners1.12%
Short Float %13.09%
Short Ratio10.18
PTGX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.26 | 374.127B | ||
| AMGN | AMGEN INC | 15.33 | 188.572B | ||
| GILD | GILEAD SCIENCES INC | 16.01 | 175.711B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.9 | 112.769B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 81.989B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.86 | 43.4B | ||
| INSM | INSMED INC | N/A | 34.527B | ||
| NTRA | NATERA INC | N/A | 29.881B | ||
| BIIB | BIOGEN INC | 11.19 | 26.402B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.48 | 25.496B | ||
| MRNA | MODERNA INC | N/A | 20.576B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.173B | ||
| INCY | INCYTE CORP | 12.52 | 19.083B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTGX
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 132 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Company Info
IPO: 2016-08-11
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560 US
CEO: Dinesh V. Patel
Employees: 132
Phone: 13026365401
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you describe the business of PROTAGONIST THERAPEUTICS INC?
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 132 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
What is the current price of PTGX stock?
The current stock price of PTGX is 102.09 USD. The price decreased by -1.6% in the last trading session.
What is the dividend status of PROTAGONIST THERAPEUTICS INC?
PTGX does not pay a dividend.
How is the ChartMill rating for PROTAGONIST THERAPEUTICS INC?
PTGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for PTGX stock?
19 analysts have analysed PTGX and the average price target is 114.5 USD. This implies a price increase of 12.15% is expected in the next year compared to the current price of 102.09.
What sector and industry does PROTAGONIST THERAPEUTICS INC belong to?
PROTAGONIST THERAPEUTICS INC (PTGX) operates in the Health Care sector and the Biotechnology industry.
When does PROTAGONIST THERAPEUTICS INC (PTGX) report earnings?
PROTAGONIST THERAPEUTICS INC (PTGX) will report earnings on 2026-05-04, after the market close.